[ 177 Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: a real-world study.

Swayamjeet SatapathyMadhav Prasad YadavSanjana BallalRanjit Kumar SahooChandrasekhar Bal

Published in: European journal of nuclear medicine and molecular imaging (2024)

Lu]Lu-PSMA-617 is a safe and effective option as a first-line treatment in mCRPC. Further trials are needed to definitively establish its role as an upfront treatment modality in this setting.

Keyphrases

pet ct
pet imaging
computed tomography
mesenchymal stem cells
bone marrow
positron emission tomography
cell therapy